Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
AIDS-Opportunistic Illness Mortality Lower but Still a Risk

Survival after the first diagnosis of AIDS-opportunistic illness (OI) has markedly improved since 1981, but some AIDS-OIs still carry a much higher mortality risk than others, according to a survival analysis published online June 3 in the Journal of Infectious Diseases.

Published
08 June 2015
From
Medscape
Early HIV Treatment Is Essential, But So Is Testing And Linkage To Care

Last week’s announcement of the Strategic Timing of AntiRetroviral Treatment (START) trial results confirms what many experts have long believed — early treatment for HIV reduces illness and death. While START further establishes the vital role of early antiretroviral therapy (ART), many questions remain on how to actually bring the life-saving benefits of treatment to individual patients.

Published
05 June 2015
From
Health Affairs (blog)
Perspectives on Post-Treatment Control of HIV

Several recent papers offer perspectives on the possibility of achieving post-treatment control of HIV replication by starting antiretroviral therapy (ART) during acute infection.

Published
03 June 2015
From
The Body
Transmitted HIV drug resistance is persistent but is not harming treatment responses in the UK

A study that looks at the genetic makeup of archived samples of drug-resistant HIV in the UK has found evidence that some drug-resistant strains of HIV are

Published
03 June 2015
By
Gus Cairns
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide (F/TAF) for HIV Treatment

Gilead Sciences, Inc. today announced that the company’s Marketing Authorization Application (MAA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) has been fully validated and is now under evaluation by the European Medicines Agency (EMA). - See more at: http://www.gilead.com/news/press-releases/2015/5/european-medicines-agency-validates-gileads-marketing-application-for-fixeddose-combination-of-emtricitabine-and-tenofovir-alafenamide-for-hiv-treatment?#sthash.jLacUtX1.dpuf

Published
02 June 2015
From
Gilead
The Independent claims HPV vaccine unsafe. Science says The Independent is wrong.

The Independent is the latest newspaper to do a hack job on the safety of the HPV vaccine and stoke false concerns about safety by publishing this poorly researched and alarmist piece on Sunday written by Paul Gallagher.

Published
02 June 2015
From
Dr. Jen Gunter (blog)
Almost Three Quarters of HIV/HCV Group May Have DDA-ARV Interactions

Among 125 HIV/HCV-coinfected people taking antiretrovirals in a Denver group, 70% could have moderate or severe interactions with one of four common direct-acting antiviral (DAA) regimens for HCV.

Published
02 June 2015
From
NATAP
New START Data Fill in When to Start ART, Now the Question is How

It's critical to recognize that figuring out when to start is only part of the puzzle. The question of how to start is equally critical and isn’t going to be settled by any randomized trial. The how concerns the environment in which individuals are offered treatment, the services that are part of that offer—peer support, community-based refills, non-biased provider care, among others—and the ways that the decision to start is framed.

Published
29 May 2015
From
AVAC
START findings highlight treatment divide

The START data show that basing treatment initiation on immune cell count is a form of rationing. But whether, how soon, and even how the findings will change clinical practice is another question.

Published
28 May 2015
From
Science Speaks
UNAIDS welcomes further evidence that starting antiretroviral therapy early saves lives

“Every person living with HIV should have immediate access to life-saving antiretroviral therapy,” said Michel Sidibé, Executive Director of UNAIDS. “Delaying access to HIV treatment under any pretext is denying the right to health.”

Published
28 May 2015
From
UNAIDS

Filter by country